Michael K. Kießling

Author

Michael K. Kießling

Also Known As

Kiessling, Michael, M. Kiessling, M.K. Kiessling, Michael K. Kiessling, Michael K. Kießling, Michael Kiessling, Michael Kießling

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

University Hospital of Zurich Heidelberg University German Cancer Research Center University Hospital Heidelberg University of Zurich

About

Michael K. Kießling is an author at University Hospital of Zurich specializing in medicine, cell biology, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	183
2	Cell Biology	3	3	183
3	Natural Sciences	1	1	136
4	Biochemistry	1	1	136
5	Immunology	1	1	13

Michael K. Kießling

Publications

839

Citations

H-Index

Page 1

	Year	Citations
Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells Hugh Gannon, Tao Zou, Michael K. Kießling, Nature Communications	2018	244
Novel Role for Mitochondria: Protein Kinase Cθ-Dependent Oxidative Signaling Organelles in Activation-Induced T-Cell Death Marcin M. Kamiński, Michael K. Kießling, Dorothee Süss, Molecular and Cellular Biology ApoptosisCell DeathReactive Oxygen SpeciesCell Death MechanismsOxidative Stress	2007	136
Inhibition of Constitutively Activated Nuclear Factor-κB Induces Reactive Oxygen Species- and Iron-Dependent Cell Death in Cutaneous T-Cell Lymphoma Michael K. Kießling, Claus D. Klemke, Marcin M. Kamiński, Cancer Research	2009	114
Trimethoprim–metformin interaction and its genetic modulation by <scp>OCT</scp>2 and <scp>MATE1</scp> transporters Barbara Grün, Michael K. Kießling, Jürgen Burhenne, British Journal of Clinical Pharmacology	2013	74
High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade Michael K. Kießling, Patrick A. Oberholzer, Chandrani Mondal, Blood	2011	74
Mutant HRAS as novel target for MEK and mTOR inhibitors Michael K. Kießling, Alessandra Curioni‐Fontecedro, Panagiotis Samaras, Oncotarget	2015	59
Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening Michael K. Kießling, Sven Schuierer, Silke Stertz, BMC Genomics	2016	43
Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma Michael K. Kießling, Alessandra Curioni‐Fontecedro, Panagiotis Samaras, PLoS ONE Nras Mutant NeuroblastomaCancer ResearchNeuroblastoma RasMedicineReceptor Tyrosine Kinase	2016	34
Targeting ALK in Neuroendocrine Tumors of the Lung Dilara Akhoundova, Martina Haberecker, Ralph Fritsch, Frontiers in Oncology	2022	20
Inhibition of NF‐κB induces a switch from CD95L‐dependent to CD95L‐independent and JNK‐mediated apoptosis in T cells Michael K. Kießling, Björn Linke, Markus Brechmann, FEBS Letters	2010	18

Page 1